Linda Pissott Reig, Shareholder in the firm's FDA & Biotechnology practice, comments on Pfizer Inc.'s suit alleging Johnson & Johnson stopped a biosimilar, a lower-priced version of an expensive drug.  The lawsuit is the first of its kind. Read "J&J Argues That Pfizer is Whining About Competing With Remicade" in STAT News.